<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795052</url>
  </required_header>
  <id_info>
    <org_study_id>MDSC-NEST</org_study_id>
    <nct_id>NCT02795052</nct_id>
  </id_info>
  <brief_title>Neurologic Stem Cell Treatment Study</brief_title>
  <acronym>NEST</acronym>
  <official_title>Neurologic Bone Marrow Derived Stem Cell Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MD Stem Cells</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Healing Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MD Stem Cells</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a human clinical study involving the isolation of autologous bone marrow derived stem
      cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in
      order to determine if such a treatment will provide improvement in neurologic function for
      patients with certain neurologic conditions. http://mdstemcells.com/nest/
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Various clinical studies have registered with the National Institutes of Health (NIH) to
      study neurologic diseases and damage. There have also been a number of journal reports of the
      benefits of treatment with BMSC for diseases and damage to nervous tissue. The investigators
      hope to add to the volume of literature regarding the use of BMSC in those neurologic
      diseases and conditions identified as likely to respond to this treatment.

      Intravenous administration of BMSC is a well-established approach to neurologic disease and
      injury with much support for its effectiveness in the pre-clinical and clinical literature.
      BMSC and the associated bone marrow fraction are posited to have a number of different
      mechanisms by which they may potentially improve neurologic function. In regards their
      ability to penetrate the blood-brain barrier for potential neuronal transdifferentiation and
      direct impact on the neurons and glial tissue within the brain, it should be remembered that
      within the diencephalon there are specific circumventricular organs which lie in the wall of
      the third ventricle. These are noteworthy for a significantly diminished blood-brain barrier
      and glial limitans which facilitates their function of coordinating homeostatic mechanisms of
      the endocrine and nervous systems. Therefore the investigators believe entry of BMSC may be
      facilitated in this area of the brain.

      In addition to Arm 1 providing intravenous BMSC, the NEST Study provides a treatment Arm 2
      which combines intravenous BMSC with topical application of BMSC to the lower 1/3 of the
      nasal passages as a means of introducing BMSC to the Central Nervous System (CNS). This is
      applied bilaterally to the inferior nasal conchas and meatuses. The Trigeminal Nerve or 5th
      Cranial Nerve is a paired, large sensory and motor nerve with multiple branches. It provides
      sensation to the surface and interior structures of the face including the nasal mucosa that
      lines the nose. The nerves of the Trigeminal Nerve providing sensation to this area converge
      and enter the brain at the level of the pons. There is documentation in the scientific
      literature that intranasal delivery of BMSC allows the BMSC to follow the pathways of the
      trigeminal nerve, facilitating entry into the parenchyma and cerebral spinal fluid (CSF) for
      effects on the CNS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activities of Daily Living (ADL)</measure>
    <time_frame>3 to 12 months</time_frame>
    <description>Activities of Daily Living (ADL) will be assessed at 3,6 and 12 months following the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurologic Functioning</measure>
    <time_frame>3 to 12 months</time_frame>
    <description>Deficits of neurologic function identified by the patient as impaired prior to treatment will be assessed. As examples, neurologic functions may include speech, balance, hearing, gait, strength, pain, parasthesias, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neurologic Disorders</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Neurodegenerative Diseases</condition>
  <condition>Neurological Disorders</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Intravenous BMSC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2- Intravenous and Intranasal BMSC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous BMSC</intervention_name>
    <description>Autologous Bone Marrow Derived Stem Cells provided intravenous.</description>
    <arm_group_label>Arm 1 - Intravenous BMSC</arm_group_label>
    <arm_group_label>Arm 2- Intravenous and Intranasal BMSC</arm_group_label>
    <other_name>IV BMSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intranasal BMSC</intervention_name>
    <description>Autologous Bone Marrow Derived Stem Cells provided intranasal (lower 1/3 of nasal passages).</description>
    <arm_group_label>Arm 2- Intravenous and Intranasal BMSC</arm_group_label>
    <other_name>IN BMSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have documented functional damage to the central or peripheral nervous system unlikely
             to improve with present standard of care.

          2. Be at least 6 months post-onset of the disease.

          3. If under current medical therapy (pharmacologic or surgical treatment) for the
             condition be considered stable on that treatment and unlikely to have reversal of the
             associated neurologic functional damage as a result of the ongoing pharmacologic or
             surgical treatment.

          4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement
             with BMSC treatment and be at minimal risk of any potential harm from the procedure.

          5. Be over the age of 18 and capable of providing informed consent.

          6. Be medically stable and able to be medically cleared by their primary care physician
             or a licensed primary care practitioner for the procedure. Medical clearance means
             that in the estimation of the primary care practitioner, the patient can reasonably be
             expected to undergo the procedure without significant medical risk to health.

        Exclusion Criteria:

          1. All patients must be capable of an adequate neurologic examination and evaluation to
             document the pathology. This will include the ability to cooperate with the exam.

          2. Patients must be capable and willing to undergo follow up neurologic exams with the
             sub-investigators or their own neurologists as outlined in the protocol.

          3. Patients must be capable of providing informed consent.

          4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a
             significant risk of harm to the patient's general health or to their neurologic
             function. .

          5. Patients who are not medically stable or who may be at significant risk to their
             health undergoing the procedure will not be eligible.

          6. Women of childbearing age must not be pregnant at the time of treatment and should
             refrain from becoming pregnant for 3 months post treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>MD Stem Cells</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Healing Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Levy, MD</last_name>
    <phone>203-423-9494</phone>
    <email>stevenlevy@mdstemcells.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Healing Institute</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Levy, MD</last_name>
      <phone>203-423-9494</phone>
      <email>stevenlevy@mdstemcells.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey N Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Al Zahra Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Levy, MD</last_name>
      <phone>203-423-9494</phone>
      <email>stevenlevy@mdstemcells.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schi√∂th HB, Benedict C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013 Oct;30(10):2475-84. doi: 10.1007/s11095-012-0915-1. Epub 2012 Nov 8. Review.</citation>
    <PMID>23135822</PMID>
  </reference>
  <reference>
    <citation>Jiang Y, Zhu J, Xu G, Liu X. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv. 2011 May;8(5):623-32. doi: 10.1517/17425247.2011.566267. Epub 2011 Mar 19. Review.</citation>
    <PMID>21417782</PMID>
  </reference>
  <reference>
    <citation>Bhasin A, Srivastava M, Bhatia R, Mohanty S, Kumaran S, Bose S. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med. 2012 Nov 26;8(3):181-9. eCollection 2012.</citation>
    <PMID>24693196</PMID>
  </reference>
  <reference>
    <citation>Teixeira FG, Carvalho MM, Sousa N, Salgado AJ. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci. 2013 Oct;70(20):3871-82. doi: 10.1007/s00018-013-1290-8. Epub 2013 Mar 1. Review.</citation>
    <PMID>23456256</PMID>
  </reference>
  <reference>
    <citation>Lescaudron L, Naveilhan P, Neveu I. The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases. Curr Med Chem. 2012;19(35):6018-35. Review.</citation>
    <PMID>22963567</PMID>
  </reference>
  <reference>
    <citation>Laroni A, de Rosbo NK, Uccelli A. Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. Immunol Lett. 2015 Dec;168(2):183-90. doi: 10.1016/j.imlet.2015.08.007. Epub 2015 Aug 18. Review.</citation>
    <PMID>26296458</PMID>
  </reference>
  <reference>
    <citation>Anbari F, Khalili MA, Bahrami AR, Khoradmehr A, Sadeghian F, Fesahat F, Nabi A. Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury. Neural Regen Res. 2014 May 1;9(9):919-23. doi: 10.4103/1673-5374.133133.</citation>
    <PMID>25206912</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurologic Disease</keyword>
  <keyword>Cerebral Vascular Accident</keyword>
  <keyword>Stroke</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Parkinsons Disease</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Neurodegeneration</keyword>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Cerebral Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://mdstemcells.com/nest/</doc_url>
      <doc_comment>http://mdstemcells.com/nest/</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

